Structure-based Design and Synthesis of Novel FXIa Inhibitors Targeting the S2' Subsite for Enhanced Antithrombotic Efficacy

Overview

Journal Mol Divers

Date 2024 Nov 8

PMID 39514169

Authors

Jie Wu

Hao Yue

Xiaoqian Wang

Yaning Yao

Nan Du

Ping Gong

Affiliations

Soon will be listed here.

Abstract

Factor XIa (FXIa), a key component of the intrinsic coagulation pathway, has recently been recognized as a safe and effective target for antithrombotic therapy. Research indicates that FXIa inhibitors can lower bleeding risk compared to novel oral anticoagulants. In this study, we designed and synthesized a series of novel FXIa inhibitors based on the structure of Asundexian, with a particular focus on optimizing the P2' region to enhance binding to the S2' subsite of FXIa. This strategy led to the discovery of compound F47, which demonstrated significantly greater FXIa inhibition (IC = 2.0 nM) compared to Asundexian (IC = 5.0 nM). F47 also showed excellent anticoagulant activity in the aPTT assay (EC = 0.4 μM), with strong efficacy and minimal impact on the extrinsic coagulation pathway. Additionally, F47 exhibited inhibitory activity against plasma kallikrein (PKal), with selectivity comparable to that of Asundexian. The compound also displayed acceptable stability in human liver microsomal stability assays. Molecular modeling revealed that F47 binds tightly to the S1, S1', and S2' pockets of FXIa while maintaining key interactions; notably, its P2' moiety forms two additional π-π stacking interactions with the crucial amino acid TYR143. Further studies demonstrated that F47 exhibits dose-dependent antithrombotic efficacy in a rat FeCl-induced thrombosis model. Ongoing research aims to further elucidate the potential of compound F47 as a promising lead in antithrombotic therapy.

References

Xu G, Liu Z, Wang X, Lu T, DesJarlais R, Thieu T . Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions. J Med Chem. 2022; 65(15):10419-10440. DOI: 10.1021/acs.jmedchem.2c00442. View

Wells P, Forgie M, Rodger M . Treatment of venous thromboembolism. JAMA. 2014; 311(7):717-28. DOI: 10.1001/jama.2014.65. View

Al-Horani R, Desai U . Factor XIa inhibitors: A review of the patent literature. Expert Opin Ther Pat. 2016; 26(3):323-45. PMC: 4941829. DOI: 10.1517/13543776.2016.1154045. View

Wong P, Crain E, Watson C, Schumacher W . A small-molecule factor XIa inhibitor produces antithrombotic efficacy with minimal bleeding time prolongation in rabbits. J Thromb Thrombolysis. 2011; 32(2):129-37. DOI: 10.1007/s11239-011-0599-0. View

Holbrook A, Pereira J, Labiris R, McDonald H, Douketis J, Crowther M . Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005; 165(10):1095-106. DOI: 10.1001/archinte.165.10.1095. View

Hirsh J, Anand S, Halperin J, Fuster V . Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation. 2001; 103(24):2994-3018. DOI: 10.1161/01.cir.103.24.2994. View

Patel N, Patel D, Murumkar P, Yadav M . Contemporary developments in the discovery of selective factor Xa inhibitors: A review. Eur J Med Chem. 2016; 121:671-698. DOI: 10.1016/j.ejmech.2016.05.039. View

Ageno W, Gallus A, Wittkowsky A, Crowther M, Hylek E, Palareti G . Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e44S-e88S. PMC: 3278051. DOI: 10.1378/chest.11-2292. View

Hauel N, Nar H, Priepke H, Ries U, Stassen J, Wienen W . Structure-based design of novel potent nonpeptide thrombin inhibitors. J Med Chem. 2002; 45(9):1757-66. DOI: 10.1021/jm0109513. View

10.

Pinto D, Orwat M, Koch S, Rossi K, Alexander R, Smallwood A . Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood.... J Med Chem. 2007; 50(22):5339-56. DOI: 10.1021/jm070245n. View

11.

Xue T, Ding S, Guo B, Zhou Y, Sun P, Wang H . Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor. J Med Chem. 2014; 57(18):7770-91. DOI: 10.1021/jm501045e. View

12.

Urooj F, Kulkarni A, Stapleton D, Kaluski E . New Oral Anticoagulants in Nonvalvular Atrial Fibrillation. Clin Cardiol. 2016; 39(12):739-746. PMC: 6490750. DOI: 10.1002/clc.22582. View

13.

Xie Z, Tian Y, Lv X, Xiao X, Zhan M, Cheng K . The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. Eur J Med Chem. 2018; 146:299-317. DOI: 10.1016/j.ejmech.2018.01.067. View

14.

Yeh C, Hogg K, Weitz J . Overview of the new oral anticoagulants: opportunities and challenges. Arterioscler Thromb Vasc Biol. 2015; 35(5):1056-65. DOI: 10.1161/ATVBAHA.115.303397. View

15.

Hughes S, Szeki I, Nash M, Thachil J . Anticoagulation in chronic kidney disease patients-the practical aspects. Clin Kidney J. 2015; 7(5):442-9. PMC: 4379338. DOI: 10.1093/ckj/sfu080. View

17.

Al-Horani R, Afosah D . Recent advances in the discovery and development of factor XI/XIa inhibitors. Med Res Rev. 2018; 38(6):1974-2023. PMC: 6173998. DOI: 10.1002/med.21503. View

18.

Fredenburgh J, Weitz J . New anticoagulants: Moving beyond the direct oral anticoagulants. J Thromb Haemost. 2020; 19(1):20-29. DOI: 10.1111/jth.15126. View

19.

Wang X, Cheng Q, Xu L, Feuerstein G, Hsu M, Smith P . Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemost. 2005; 3(4):695-702. DOI: 10.1111/j.1538-7836.2005.01236.x. View

20.

Seligsohn U . Factor XI deficiency in humans. J Thromb Haemost. 2009; 7 Suppl 1:84-7. DOI: 10.1111/j.1538-7836.2009.03395.x. View

21.

Salomon O, Steinberg D, Zucker M, Varon D, Zivelin A, Seligsohn U . Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost. 2010; 105(2):269-73. DOI: 10.1160/TH10-05-0307. View